|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/00 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| C07K 16/28 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3819007 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19208417.6 |
| Date of filing the European patent application | 2019-11-11 | |
| (97) | Date of publication of the European application | 2021-05-12 |
| (45) | Date of publication and mention of the grant of the patent | 2024-07-10 |
| (46) | Date of publication of the claims translation | 2024-10-10 |
| (72) |
Stieglmaier, Julia , DE
Huber, Birgit , DE
Minella, Alexander , US
Upreti, Vijay , US
|
| (73) |
Amgen Research (Munich) GmbH ,
Staffelseestrasse 2, 81477 München,
DE
Amgen Inc. , One Amgen Center Drive, Thousand Oaks, CA 91320, US |
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Dozavimo režimas, skirtas anti-BCMA agentams |
| DOSING REGIMEN FOR ANTI-BCMA AGENTS |
| Payment date | Validity (years) | Amount | |
| 2025-10-22 | 7 | 162.00 EUR |
| 2026-11-11 |